Wayne Doyle

• Design cell–type–specific RNA sequences to optimize therapeutic potential

• Validate manufacturing robustness with sequencing-based analysis, including assessment of dsRNA impurities and poly(A) tail length

• Evaluate delivery vehicle effects on RNA stability and cellular uptake